Welcome to our dedicated page for Inmed Pharmaceuticals SEC filings (Ticker: INM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for InMed Pharmaceuticals Inc. (NASDAQ: INM), a British Columbia–incorporated pharmaceutical drug development company. These documents provide detailed information on InMed’s proprietary small molecule drug candidates targeting CB1/CB2 receptors, its Alzheimer’s, ocular and dermatological programs, and the commercial activities of its rare cannabinoid subsidiary BayMedica.
Through periodic and current reports, investors can review InMed’s audited and unaudited consolidated financial statements, management’s discussion and analysis, and segment information covering both pharmaceutical development and BayMedica’s commercial operations. Filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q describe sales from BayMedica, research and development spending on programs like INM-901 and INM-089, general and administrative expenses and cash resources.
Current reports on Form 8-K document material events, including financial result announcements, progress updates on INM-901 pharmacokinetic and preclinical studies, legislative developments affecting BayMedica’s rare cannabinoid business, board appointments, and details of private placements and equity purchase agreements. Proxy materials such as the definitive proxy statement on Schedule 14A outline the agenda for the annual general and special meeting of shareholders, including director elections, auditor appointments and share issuance proposals under a Standby Equity Purchase Agreement.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight key points, helping readers quickly understand complex disclosures such as multi-segment financials, capital structure changes and regulatory risk discussions. Users can monitor real-time updates from EDGAR, review historical filings across multiple years and examine items related to governance, such as board composition and auditor approvals, all in one organized view for INM.
InMed Pharmaceuticals (INM) filed a preliminary proxy for its annual general and special meeting, to be held virtually by telephone on December 17, 2025 at 4:00 p.m. PST. The record date is October 22, 2025, when 2,804,186 Common Shares were issued and outstanding.
Shareholders will receive the FY2025 audited financial statements (no vote), elect five directors (the Board is nominating five; one incumbent will not stand for re‑election), and vote on additional items including the ratification of CBIZ CPAs P.C. as auditor. Directors are elected by plurality; other proposals require a simple majority of votes cast. Auditor ratification is routine; the director election is non‑routine, so broker non‑votes will not count toward director elections. Quorum requires two persons holding not less than 33⅓% of the voting shares.
The Board reports that all directors other than the CEO are independent and maintains Audit, Compensation, and Governance/Nomination committees. As of the record date, Sabby Volatility Warrant Master Fund, Ltd. beneficially owned 280,138 shares (9.99%).
InMed Pharmaceuticals (INM) filed Amendment No. 1 to its Annual Report to amend and restate Part III—Items 10–14. The update replaces director and executive biographies, compensation, beneficial ownership, related-party transactions, director independence, and auditor fee disclosures, and removes the prior reference to incorporation by reference from a proxy. Other disclosures remain unchanged.
The company reports 2,384,186 common shares outstanding as of September 17, 2025 and an aggregate market value of non‑affiliates of $3,316,582 as of December 31, 2024. FY2025 audit fees were $212,000 (total fees $229,000) with CBIZ CPAs P.C. following its acquisition of Marcum LLP’s attest business on November 1, 2024. The Board’s committees (Audit, Compensation, Governance/Nomination) are composed of independent directors; the company maintains insider trading, anti‑hedging, and clawback policies. FY2025 CEO total compensation was $396,973. A beneficial ownership table as of October 22, 2025 lists Sabby Volatility Warrant Master Fund at 280,138 shares (9.99%), subject to stated beneficial ownership limits.
InMed Pharmaceuticals (INM) reported an initial statement of beneficial ownership by a director. The filing lists an employee stock option to purchase 3,500 common shares at an exercise price of $2.1, with an expiration date of 10/16/2030.
The event date is 10/14/2025. According to the vesting terms, the options were granted on 10/17/2025 and will vest monthly, in arrears: 98 options on the 17th of each month for 35 months, and 70 options on 10/17/2025. Ownership is reported as Direct.
InMed Pharmaceuticals (INM) reported a director’s Form 4 for an employee stock option grant of 3,500 options at an exercise price of $2.1 per share on Oct 17, 2025. The options expire on Oct 16, 2030.
Vesting is monthly in arrears: 98 options will vest on the 17th of each month for 35 months, and 70 options will vest on Oct 17, 2025, as described in the filing. Following the grant, the reporting person holds 3,500 derivative securities directly.
InMed Pharmaceuticals (INM) disclosed an initial beneficial ownership filing. A director submitted a Form 3 indicating their status as a Director and reporting no securities beneficially owned as of the event date 10/09/2024.
The Form 3 was filed by one reporting person and lists no direct or indirect holdings in either non-derivative or derivative securities. The filing is signed "/s/ Neil Klompas" and dated 10/17/2025.
InMed Pharmaceuticals appointed John Bathery to its Board, effective October 14, 2025, and increased the Board size to six members. His term runs until immediately before the company’s 2025 Annual General Meeting. Compensation follows the standard non-employee director program, including an annual retainer of US50,000; he also signed the company’s standard indemnification agreement.
Bryan Baldasare notified the company on October 15, 2025 that he will not stand for re-election at the 2025 Annual General Meeting, citing increasing professional obligations. The company stated there is no disagreement with Mr. Baldasare on matters of operations, policies, or practices.
InMed Pharmaceuticals (INM) reported an administrative update. On October 10, 2025, the company announced the meeting, record date, and related details for its 2025 annual general and special meeting of shareholders, as reflected in a revised submission to Canada’s SEDAR system. The notice was furnished via an 8-K under Item 8.01, with the SEDAR filing listed as Exhibit 99.1.
InMed Pharmaceuticals (INM) appointed Neil Klompas to its board of directors, effective October 9, 2025, and increased the board size to five members. His term runs until immediately before the 2025 Annual General Meeting. The company noted there are no related party transactions or family relationships tied to his appointment.
Klompas will receive non-employee director compensation consistent with company policy, including an annual retainer of US$50,000, with potential additional amounts for committee service. InMed furnished a press release as Exhibit 99.1.
InMed Pharmaceuticals Inc. filed a current report to note that on September 23, 2025 it announced financial results for its fiscal year ending June 30, 2025 and gave a business update. The update covered its pharmaceutical drug development programs and the commercial segment of its wholly owned subsidiary, BayMedica, LLC. The related news release is furnished as Exhibit 99.1 under a Regulation FD disclosure and is not deemed filed or incorporated by reference unless specifically stated in another filing.
InMed Pharmaceuticals Inc. reported that on September 23, 2025 it announced the meeting date, record date and related details for its 2025 annual meeting of shareholders through a filing on Canada’s SEDAR system. The company is making that SEDAR disclosure available to U.S. investors as Exhibit 99.1 to this report.
The company states that the information in this report, including Exhibits 99.1 and 99.2, is being furnished rather than filed under the U.S. securities laws, which limits how it is treated for liability purposes and incorporation by reference into other securities filings.
FAQ
What is the current stock price of Inmed Pharmaceuticals (INM)?
What is the market cap of Inmed Pharmaceuticals (INM)?
